The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

The WHO has recognised iron deficiency anaemia (IDA) as the most common nutritional
deficiency in the world, with 30% of the population being affected with this condition …

Iron deficiency (ID) is common in patients with cardiovascular disease. Up to 60% of patients
with coronary artery disease, and an even higher proportion of those with heart failure (HF) …

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. Circulating
biomarkers reflecting pathophysiological pathways involved in HF development and …

The 2021 Update to the 2017 American College of Cardiology (ACC) Expert Consensus
Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues …

Abstract Background and Aims Whereas a beneficial effect of intravenous ferric
carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron …

Iron deficiency anaemia is a global health concern affecting children, women and the
elderly, whilst also being a common comorbidity in multiple medical conditions. The …

Background: Iron deficiency is common in heart failure and associated with worse outcomes.
We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial …

Aims For patients with heart failure (HF) and iron deficiency (ID), randomized trials suggest
that intravenous (IV) iron reduces hospitalizations for heart failure (HHF), but uncertainty …